๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Maridebart cafraglutide

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 13 trials in our USA, UK and China registers that name Maridebart cafraglutide as an intervention. Synced 24 Sep 2026
13Trials tracked
7Recruiting now
1Lead sponsor
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Maridebart cafraglutide is named as a drug or biological intervention in 13 clinical trials in our USA, UK and China trial registers, 7 of which are recruiting. The lead sponsor is Amgen. Registered phases: Phase 3, Phase 2 and Phase 1. Conditions studied include Obesity; Overweight; Obstructive Sleep Apnea.

01

Clinical trials of Maridebart cafraglutide

13 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07037433 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (ClinicalTrials.gov ↗)
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Phase 3 Recruiting Amgen UK, USA, China
NCT07037459 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (ClinicalTrials.gov ↗)
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Phase 3 Recruiting Amgen UK, USA, China
NCT07226765 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy (ClinicalTrials.gov ↗)
Obstructive Sleep Apnea
Phase 3 Recruiting Amgen USA
NCT07575399 Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) (ClinicalTrials.gov ↗)
Obesity or Overweight
Phase 3 Recruiting Amgen USA
NCT07684144 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) (ClinicalTrials.gov ↗)
Obesity, Overweight, Diabetes Mellitus, Type 2
Phase 3 Recruiting Amgen USA
NCT07684235 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) (ClinicalTrials.gov ↗)
Obesity, Overweight
Phase 3 Recruiting Amgen USA
NCT07441252 A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight (ClinicalTrials.gov ↗)
Overweight or Obesity and Elevated Liver Fat
Phase 2 Recruiting Amgen USA
NCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (ClinicalTrials.gov ↗)
Obesity
Phase 3 Active, closed Amgen UK, USA
NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (ClinicalTrials.gov ↗)
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Phase 3 Active, closed Amgen UK, USA
NCT07225686 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (ClinicalTrials.gov ↗)
Obesity, Obstructive Sleep Apnea
Phase 3 Active, closed Amgen USA
NCT06660173 A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) (ClinicalTrials.gov ↗)
Type 2 Diabetes Mellitus (T2DM)
Phase 2 Active, closed Amgen USA
NCT07160257 A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and ฮฒ-cell Function in Participants With Type 2 Diabetes Mellitus (ClinicalTrials.gov ↗)
Type 2 Diabetes Mellitus
Phase 1 Active, closed Amgen USA
NCT07523711 Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity (ClinicalTrials.gov ↗)
Overweight, Obesity
Phase 1 Active, closed Amgen USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

12 conditions
Condition (as registered)Trials
Obesity7
Overweight4
Obstructive Sleep Apnea2
Heart Failure With Preserved Ejection Fraction1
Heart Failure With Mildly Reduced Ejection Fraction1
Atherosclerotic Cardiovascular Disease1
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight1
Type 2 Diabetes Mellitus (T2DM)1
Overweight or Obesity and Elevated Liver Fat1
Diabetes Mellitus, Type 21
Type 2 Diabetes Mellitus1
Obesity or Overweight1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Amgen13
04

Trials by country register

RegisterMaridebart cafraglutide trials
Clinical trials in USA13
Clinical trials in UK4
Clinical trials in China2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Maridebart cafraglutide works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Maridebart cafraglutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.